Erasca, Inc. (ERAS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.19-0.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ERAS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| Operating Income | (302.7) | (140.9) | (179.6) | (141.5) | (247.5) | (124.9) | (109.3) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 15.5 | 16.4 | 17.9 | 16.5 | 4.6 | 2.1 | 7.6 |
| EBT, Incl. Unusual Items | — | (124.5) | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (287.2) | (124.5) | (161.7) | (125.0) | (242.8) | (122.8) | (101.7) |
| Per Share | |||||||
| Basic EPS | (0.92) | (0.44) | (0.69) | (0.83) | (1.99) | (1.85) | — |
| Diluted EPS | (0.92) | (0.44) | (0.69) | (0.83) | (1.99) | (1.85) | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | — | — |
| Basic Weighted Avg Shares | 311.3 | 283.5 | 233.8 | 150.2 | 122.0 | 66.3 | — |
| Diluted Weighted Avg Shares | 311.3 | 283.5 | 233.8 | 150.2 | 122.0 | 66.3 | — |
| Supplemental | |||||||
| EBITDA | — | (137.8) | (175.8) | (137.8) | (244.8) | (124.1) | (108.7) |
| EBIT | (302.7) | (140.9) | (179.6) | (141.5) | (247.5) | (124.9) | (109.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.